LSV Asset Management Decreases Position in The Chemours Company (NYSE:CC)

LSV Asset Management decreased its position in The Chemours Company (NYSE:CC - Free Report) by 33.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,248,400 shares of the specialty chemicals company's stock after selling 623,600 shares during the quarter. LSV Asset Management owned approximately 0.84% of Chemours worth $21,098,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of CC. GAMMA Investing LLC increased its stake in Chemours by 99.7% in the 4th quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock worth $26,000 after buying an additional 765 shares in the last quarter. Quadrant Capital Group LLC grew its position in shares of Chemours by 100.4% during the fourth quarter. Quadrant Capital Group LLC now owns 2,234 shares of the specialty chemicals company's stock worth $38,000 after purchasing an additional 1,119 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new stake in Chemours during the 4th quarter valued at approximately $48,000. KBC Group NV lifted its holdings in Chemours by 38.2% in the 4th quarter. KBC Group NV now owns 6,176 shares of the specialty chemicals company's stock worth $104,000 after purchasing an additional 1,708 shares in the last quarter. Finally, EMC Capital Management grew its holdings in Chemours by 74.6% during the 4th quarter. EMC Capital Management now owns 9,534 shares of the specialty chemicals company's stock valued at $161,000 after buying an additional 4,073 shares in the last quarter. 76.26% of the stock is owned by hedge funds and other institutional investors.

Chemours Stock Up 3.1 %

NYSE CC traded up $0.35 on Friday, reaching $11.37. 1,640,388 shares of the stock traded hands, compared to its average volume of 1,832,085. The Chemours Company has a 12 month low of $9.33 and a 12 month high of $29.21. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68. The company has a fifty day moving average price of $13.97 and a 200-day moving average price of $17.39. The company has a market cap of $1.70 billion, a price-to-earnings ratio of 19.94 and a beta of 1.84.

Chemours (NYSE:CC - Get Free Report) last issued its earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.01. Chemours had a net margin of 1.51% and a return on equity of 26.54%. The company had revenue of $1.36 billion for the quarter, compared to analysts' expectations of $1.37 billion. As a group, research analysts forecast that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, March 14th. Stockholders of record on Friday, February 28th were given a $0.25 dividend. This represents a $1.00 annualized dividend and a dividend yield of 8.80%. The ex-dividend date was Friday, February 28th. Chemours's payout ratio is 175.44%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. BMO Capital Markets dropped their target price on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating for the company in a research report on Wednesday, February 19th. Mizuho set a $15.00 price objective on Chemours in a research report on Tuesday. Truist Financial lowered their target price on Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research report on Monday. Morgan Stanley dropped their target price on Chemours from $25.00 to $22.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Finally, Barclays cut their price target on shares of Chemours from $19.00 to $16.00 and set an "equal weight" rating on the stock in a report on Tuesday, April 1st. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, Chemours presently has an average rating of "Moderate Buy" and an average target price of $21.56.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.